Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that it has initiated an open-label Phase 2 study of glembatumumab vedotin (CDX-011) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE